Pickart L R, Thaler M M
Med Hypotheses. 1980 May;6(5):545-57. doi: 10.1016/0306-9877(80)90108-5.
Plasma fibrinogen is elevated in various stressful states and conditions in which active mobilization of free fatty acids (FFA) occurs. Reduction of plasma FFA by an assortment of hypolipidemic drugs is consistently followed by a decrease in the accompanying hyperfibrinogenemia. A direct link between FFA and fibrinogen has been demonstrated in animals, and in experiments employing incubated liver slices. Based on these clinical and experimental observations, we postulate that hepatic fibrinogen synthesis is stimulated by FFA. Since fibrinogen is a major determinant of whole blood viscosity, erythrocyte aggregation, and sludging of red cells in terminal and pre-terminal blood vessels, we propose that microcirculatory blood flow may be impaired in the presence of chronically elevated plasma FFA levls. Consequently, hypolipidemic drugs may be effective in prevention of circulatory complications associated with FFA-induced hyperfibrinogenemia.
在各种应激状态以及发生游离脂肪酸(FFA)主动动员的情况下,血浆纤维蛋白原水平会升高。使用各种降血脂药物降低血浆FFA后,随之而来的高纤维蛋白原血症也会持续降低。在动物以及采用孵育肝切片的实验中,已经证实了FFA与纤维蛋白原之间存在直接联系。基于这些临床和实验观察结果,我们推测FFA会刺激肝脏纤维蛋白原的合成。由于纤维蛋白原是全血粘度、红细胞聚集以及末梢和末梢前血管中红细胞淤滞的主要决定因素,我们提出,在血浆FFA水平长期升高的情况下,微循环血流可能会受到损害。因此,降血脂药物可能对预防与FFA诱导的高纤维蛋白原血症相关的循环并发症有效。